UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other jur ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2020 Earnings Conference Call February 4, 2021 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Biren Amin - Jefferies Paul Matteis - Stifel Tazeen Ahmad - Bank of America Josh Schimmer - ...

Neurocrine® Advancing Life-Changing Discoveries in Neuroscience neurocrine.com Q4 2020 / Year-End Corporate Presentation February 4, 2021 Nasdaq: NBIX Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/o ...

| --- | --- | --- | --- | |----------------|------------------------------------------------------|-------|-------------------------------------------------| | | | | | | | Advancing Life-Changing Discoveries in Neuroscience | | Q3 2020 Corporate Presentation November 9, 2020 | | neurocrine.com | | | Nasdaq: NBIX | Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Josh Schimmer - Evercore ISI Tazeen Ahmad - Bank of America Paul Matteis - Stifel Biren Amin - Jefferies Phil Nadeau - Cowen & Company Brian Skorney ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Neurocrine® Advancing Life-Changing Discoveries in Neuroscience Q2 2020 Corporate Presentation August 3, 2020 Nasdaq: NBIX neurocrine.com Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2020 Results Conference Call August 3, 2020 4:30 PM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Paul Matteis - Stifel Phil Nadeau - Cowen and Company Brian Abrahams - RBC David Amsellem - Piper Sandler Paul Choi - Goldman Sachs Marc Goodman - SVB Leerink Bir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...

Neurocrine® Advancing Life-Changing Discoveries in Neuroscience Q1 2020 Corporate Presentation May 6, 2020 Nasdaq: NBIX neurocrine.com Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates, including INGREZZA, ONGENTYS, and our partne ...